Related Experiment Videos

[Early atherosclerosis changes in children with juvenile idiopathic arthritis]

Edyta Pietrewicz1, Mirosława Urban

  • 1Akademia Medyczna w Białymstoku, II Klinika Chorób Dzieci. klchdz2@cksr.ac.białystok.pl

Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego
|August 9, 2007
PubMed

Insights

Children with juvenile idiopathic arthritis (JIA) show early signs of atherosclerosis, including increased intima-media thickness (IMT) and homocysteine levels. These findings highlight the need for early detection methods to prevent future cardiovascular complications in JIA patients.

Area of Science:

  • Pediatrics
  • Cardiovascular Medicine
  • Rheumatology

Background:

  • Juvenile idiopathic arthritis (JIA) shares pathogenic similarities with atherosclerosis, including elevated inflammation markers, homocysteine, and lipid levels.
  • Early detection of atherosclerosis in JIA patients is crucial for preventing long-term complications like heart disease and stroke.

Purpose of the Study:

  • To assess preclinical markers of atherosclerosis, specifically serum homocysteine concentration and carotid artery intima-media thickness (IMT), in children with JIA.
  • To investigate the relationship between these markers and disease characteristics in JIA.

Main Methods:

  • The study included 40 children with JIA (aged 4-16) and 23 healthy children as a control group.
  • Measurements included serum homocysteine, C-reactive protein (CRP), lipids, and carotid artery IMT via ultrasonography.
  • Children were categorized into oligoarthritis and polyarthritis JIA subgroups.

Main Results:

  • Children with JIA exhibited a statistically significant increase in IMT compared to the control group (0.43 mm vs. 0.40 mm).
  • Polyarthritis JIA subgroup showed higher IMT and homocysteine levels than the oligoarthritis subgroup.
  • A significant correlation was found between IMT and disease duration (r=0.45), and between IMT and homocysteine levels (r=0.36).

Conclusions:

  • Children with JIA demonstrate accelerated atherosclerosis, evidenced by increased IMT and homocysteine levels.
  • Early diagnostic methods, such as IMT measurement and homocysteine assessment, are vital for identifying atherosclerosis in its preclinical stages in JIA patients.
  • These early interventions can help mitigate future cardiovascular risks in this population.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Inflammation01:38

Inflammation

Overview